The Centers for Medicare and Medicaid Services is famous for auditing the two big government health programs that it runs. But CMS faces audits also. The inspector general's office within HHS is one of the groups that keeps a close eye on CMS. And, like an internal family feud, criticism from within HHS can often be the most frank and painful. CMS is feeling the pain from a review of pharmacy acquisiton costs under Part D;' there is more coming.
Cole Werble
How much does the Centers for Medicare & Medicaid Services fear data crunching by the Office of the Inspector General?
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.
The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.
